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Abstract cDNA sequences were elucidated for two closely
related human genes which encode the precursors of two hitherto
unknown aspartic proteinases. The (pro)napsin A gene is
expressed predominantly in lung and kidney and its translation
product is predicted to be a fully functional, glycosylated aspartic
proteinase (precursor) containing an RGD motif and an
additional 18 residues at its C-terminus. The (pro)napsin B
gene is transcribed exclusively in cells related to the immune
system but lacks an in-frame stop codon and contains a number
of polymorphisms, one of which replaces a catalytically crucial
Gly residue with an Arg. Consideration is given to whether
(pro)napsin B may be a transcribed pseudogene or whether its
putative protein product undergoes rapid intracellular degrada-
tion.
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1. Introduction
Aspartic proteinases contain two internally homologous do-
mains, each of which contributes a catalytic Asp residue to the
active site which is located between the two domains [1]. Each
aspartic acid residue is found in the hallmark sequence VHy-
drophobic-Hydrophobic-Asp-Thr/Ser-GlyV which, together
with a further VHydrophobic-Hydrophobic-GlyV motif,
forms a structural feature known as a psi loop [2]. In some
enzymes, the domains are contained within a single polypep-
tide chain so that each of the motifs occurs twice within the
molecule and in the encoding gene [3].
Five aspartic proteinases are well documented to be pro-
duced in the human body. Three (pepsin, gastricsin and renin)
are secretory enzymes which not only have well-de¢ned phys-
iological roles but have also been associated with pathological
states, e.g. cancer [4]. Cathepsin D and cathepsin E are
present in intracellular compartments and are readily distin-
guished by their molecular architecture and cytomorphologi-
cal compartmentation [5]. With the exception of cathepsin E,
crystal structures have been solved for these enzymes and the
gene locus for all ¢ve enzymes has been identi¢ed and mapped
[6]. With the advent of human genome projects, ready access
to a vast array of human expressed sequence tags (ESTs) is
now possible. Interrogation of these databases for the hall-
mark sequences of aspartic proteinases, i.e. the VHydro-
phobic-Hydrophobic-Asp-Thr/Ser-GlyV plus VHydropho-
bic-Hydrophobic-GlyV motifs, gave a preliminary
indication that yet further aspartic proteinases were encoded
within the human genome. We have called these napsins (for
novel aspartic proteinases of the pepsin family).
2. Materials and methods
2.1. Detection and preparation of (pro)napsin A and B clones
The protein sequence of human procathepsin E was used as a probe
to search the human EST databases. Inspection of the predicted se-
quences of the resulting hits indicated that several contained the hall-
mark VHydrophobic-Hydrophobic-Asp-Thr-GlyV and VHydro-
phobic-Hydrophobic-GlyV motifs but the intervening sequence was
distinct from those of the ¢ve known human aspartic proteinases. The
initial EST clones that encompassed parts of (pro)napsin A were
prepared by scientists at Human Genome Services or the Institute
for Genomic Research using established EST methods [7,8].
RNA prepared from human lung, kidney and spleen was purchased
from Clontech Laboratories Inc., Palo Alto, CA, USA. Clones of
(pro)napsin B were generated from RNA isolated from human Raji
cells using the Tri-reagent kit (Sigma, Poole, UK). First strand cDNA
was synthesised by reverse transcriptase using either random hexamers
or a modi¢ed oligo(dT)17 primer as described previously [9]. An initial
PCR product spanning most of the (pro)napsin B sequence was am-
pli¢ed from random-primed cDNA using speci¢c forward (5P-TGG
GTT CAC ACC CGG CT-3P) and reverse (5P-GCC AGT CCC ACT
CGT GC-3P) primers. A 3P product (product 2) extending to the
poly(A) tail was generated, using as template cDNA that had been
synthesised using the modi¢ed oligo(dT)17 primer in a PCR ampli¢-
cation which involved an internal primer (5P-CT CAG GGT GAC
GTC CGC-3P) together with the modi¢ed oligo(dT)17 as the reverse
primer. Ampli¢ed products were all cloned into pGEM-T (Promega,
Southampton, UK). PCR ampli¢cations and dideoxy sequencing of
plasmids in both strands were performed by standard methods as
described previously [9].
2.2. Northern blotting and distinction between (pro)napsin A and B
transcripts
Human multiple tissue Northern blots (Clontech) were hybridised
with a BamHI/SalI fragment of 267 bp derived from the 3P end of
product 2, described above. This probe, which hybridises to both
(pro)napsin A and B messages because of their sequence identity
(s 90%), was radiolabelled by incorporation of [32P]dCTP (RadPrime
DNA Labelling System, Life Technologies Inc., Grand Island, NY,
USA) and puri¢ed using a CHROMA SPIN+TE-30 column (Clon-
tech). After a 1 h prehybridisation, hybridisation was carried out for
2 h using ExpressHyb bu¡er (Clontech) at 68‡C. The membrane was
washed twice in 2USSC, 0.05% SDS for 20 min, twice in 0.1USSC,
0.1% SDS at 50‡C for 20 min and exposed to X-ray ¢lm at 370‡C
with two intensifying screens. Distinction between speci¢c mRNAs for
(pro)napsins A and B was accomplished by RT-PCR using forward
(5P-T GGT GGA ATC AAG GGT GC-3P) and reverse (5P-AA GTA
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AAA GGA GAA GAC AGG-3P) primers that permit ampli¢cation of
the exon 5 region (bp 471^662; Fig. 1) of both messages. Following
cloning of the resultant amplicons into pGEM-T, restriction digestion
with NcoI/SalI con¢rmed the presence of (pro)napsin A/B inserts. A
BstXI site is present in this region of the (pro)napsin A but not the
(pro)napsin B gene. Digestion with BstXI released fragments of 164
or 129 bp depending on insert orientation from (pro)napsin A clones.
Conversely, an MspAI site present in the (pro)napsin B sequence is
absent in the (pro)napsin A clone. Digestion with MspAI releases
diagnostic fragments of 331+144 bp or 412+63 bp, depending on
insert orientation, from (pro)napsin B clones compared to an intact
fragment of 475 bp from plasmids containing the (pro)napsin A am-
plicon. Representative positive clones of each type were cloned and
sequenced.
3. Results and discussion
Interrogation of the EST databases identi¢ed a number of
entries that contained the hallmark VHydrophobic-Hydro-
phobic-Asp-Thr-GlyV and VHydrophobic-Hydrophobic-
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Fig. 1. Nucleotide sequences encoding (pro)napsins A (NapA) and B (NapB). The NapA sequence is given in full. For NapB, at any position
where no base is shown, sequence identity with NapA exists. (-) indicates the absence of a nucleotide. The TGA stop codon (bp 1261^1263) in
NapA is TGC in NapB.
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GlyV motifs of an aspartic proteinase but the intervening
nucleotide sequence predicted a protein that would have a
sequence distinct from those of the ¢ve known human aspartic
proteinases. The full-length nucleotide sequence that was
eventually determined for this new aspartic proteinase gene
(which we have called (pro)napsin A) is given in Fig. 1 with
the translated protein product shown in Fig. 2. The 1263-bp
open reading frame predicts a 420-amino acid polypeptide
consisting of four regions: a signal peptide (V24 residues),
a propart region of V40 residues, the mature enzyme (V336
residues) and a C-terminal extension of 18 residues relative to
the known C-termini of the ¢ve other human aspartic protein-
ases (Fig. 2). The functional regions in human (pro)napsin A
can be readily identi¢ed from their similarity to those in the
other human aspartic proteinases. These include (using pig
pepsin numbering) the active site VAla30-Phe31-Asp32-
Thr33-Gly34V and accompanying VIle120-Leu121-
Gly122V motifs; the VIle213-Leu214-Asp215-Thr216-
Gly217V and VIle300-Leu301-Gly302V pair and the
VTyr75-Gly76-X-Gly78 motif that is a conserved feature of
the L-hairpin loop that overlies the active site [1]. Retention of
these functionally critical residues identi¢es napsin A as a new
human aspartic proteinase. The identity (cDNA and amino
acid, respectively) of the mature region of human napsin A
(residues 1^344; Fig. 2) was 47.1 and 48.3% with human
cathepsin D, 43.6 and 48.4% with cathepsin E, 41.0 and
43.9% with human pepsin, 40.9 and 43.0% with renin, and
37.4 and 41.9% with gastricsin.
The three disulphide bonds characteristic of mammalian
aspartic proteinases are predicted to be conserved in the ma-
ture enzyme segment of human napsin A (Fig. 2). Three po-
tential N-linked oligosaccharide attachment sites are also pre-
dicted in human napsin A. The ¢rst of these (at Asn26-Phe27-
Thr28) is in the identical location to the glycosylation motif
that is present in cathepsin E from all species so far studied
[9]. The second (at Asn67-Gly68-Thr69) corresponds in loca-
tion to glycosylation sites in human renin and cathepsin D.
The ¢nal site (at Asn268; Fig. 2) does not coincide with gly-
cosylation locations in other human aspartic proteinases.
Perhaps the most distinctive features of the human napsin
A sequence, however, are located towards the C-terminal end.
An RGD motif (residues 315^317) is located immediately in
front of a four-amino acid insert that is unique amongst as-
partic proteinases. The RGD sequence constitutes the recog-
nition motif for integrin binding and might suggest a novel
function for this aspartic proteinase. An RGD sequence has
also been detected recently but at di¡erent locations in the
sequences of cardosin A, a plant aspartic proteinase [10]
and in (only) one of seven aspartic proteinases secreted by
Candida albicans [11]. In addition to this RGD sequence,
napsin A also has a C-terminal extension of 18 residues com-
pared to all the other human aspartic proteinases. The func-
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Fig. 2. Alignment of the deduced amino acid sequences of human (pro)napsin A (NapA), (pro)napsin B (NapB), mouse (pro)napsin (Mnap)
and pig pepsin(ogen) (PPep). The absence of a residue is indicated by (-) and residues in the (pro)part are designated by a su⁄x P (pig pepsin
numbering). The positions of the active site Asp residues, potential N-glycosylation sites and cysteine residues involved in disul¢de bond forma-
tion are indicated by O, 8 and b respectively. The extended C-terminal ‘tail’ of (pro)napsin B is shown as far as the ¢rst of the Lys residues
translated from the poly(A) tail of the message.
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tion of this C-terminal ‘tail’ is not immediately apparent.
Crystal structures determined for Candida aspartic proteinases
with C-terminal extensions of V9 residues show that these
residues contribute an additional strand to the 6-stranded L-
sheet that forms the base of the molecular architecture of this
family of enzymes [12]. In contrast, even longer tails have
been predicted in aspartic proteinases encoded within genes
of parasites of mammals, including man [13,14] and poultry
(Eimeria tenella [15]) and from the yeast, Saccharomyces cere-
visiae [16,17]. These yeast enzymes (Yap 3 or Yapsin 1; Mkc 7
or Yapsin 2 [16,17]) are known to be GPI-anchored and since
the extension in the E. tenella enzyme also contains the rec-
ognition motif for C-terminal truncation with concomitant
attachment of a membrane-targeting GPI anchor [18], these
aspartic proteinases may be members of a growing sub-family
that are GPI-anchored. However, the highly charged, hydro-
philic nature of the napsin A ‘tail’ suggests that this new
human aspartic proteinase cannot be classi¢ed into this sub-
family.
During our sequencing work on (pro)napsin A, it became
readily apparent that some human EST clones (e.g. Genbank
R11458 and T54068) contained a sequence that was similar to
but distinct from that of (pro)napsin A. Thus, mRNA was
isolated from human Raji cells (a B-cell line derived from
human Burkitt’s lymphoma) and reverse-transcribed (see Sec-
tion 2). The predominant nucleotide sequence elucidated for
the (pro)napsin B cDNA clones generated is shown in Fig. 1
with the translation product in Fig. 2. However, ¢ve poly-
morphisms were detected in this cDNA sequence. Four of
these (AAT/C at nucleotide 666; Fig. 1; CCA/T at 675;
GGC/T/G at 711; and GCA/C at bp 1296) were silent. The
remaining G/C variation at nucleotide 562 alters the resultant
codon from GGC to CGC (Gly to Arg; see below). The over-
all sequence identities between (pro)napsin B and A are 91.2%
(nucleotide) and 86% (amino acid). The protein sequence pre-
dicted by the (pro)napsin B gene has two glycosylation motifs
(at Asn26 and Asn268; Fig. 2) in common with (pro)napsin
A, but the Asn67-Gly68-Thr69 motif in napsin A, renin and
cathepsin D is not present. However, an adjacent Asn59-
Ala60-Ser61 motif in the predicted napsin B sequence is in a
position that does not correspond to any known glycosylation
motif in other aspartic proteinases. The predicted napsin B
sequence also contains the RGD motif immediately preceding
a four-residue insert that was discussed earlier for napsin A.
Most of the other di¡erences between mature napsin A and
the predicted sequence of the putative napsin B polypeptide
appear to cluster in the region of the active site of the en-
zyme(s), on the basis of homology modelling (not shown).
However, the most unusual features predicted by the (pro)-
napsin B sequence are (i) that it does not contain an in-frame
stop codon and (ii) that the residues at positions 120^122 were
predicted to be VIle-Leu-ArgV in ¢ve of 11 independently
generated clones but to be VIle-Leu-GlyV in the remaining
six (Fig. 2). The polymorphism in this CGC/GGC codon was
established by analysing (pro)napsin B segments of di¡erent
lengths, generated from di¡erent cell types and from genomic
as well as cDNA origin. Of the ¢ve containing the Arg var-
iant, one clone was isolated from a foetal spleen cDNA li-
brary, whilst the other four were independently generated by
RT-PCR from RNA extracted from human Raji cells. Of the
six Gly containing clones, one was isolated from a foetal
spleen cDNA library, and ¢ve were generated independently
(two from reverse-transcribed adult spleen RNA and three
from separate preparations of genomic DNA isolated respec-
tively from human AGS, human Kato III (both gastric ad-
enocarcinoma cell lines) and human white blood cells) using
the exon 5 primers, as described in Section 2. The VIle-Leu-
GlyV sequence forms the L-strand or thread of the psi loop
in the N-terminal domain of all vertebrate/fungal aspartic
proteinases [2]. By de¢nition (see Section 1) this sequence
must be maintained as VHydrophobic-Hydrophobic-GlyV
in order for the psi loop to adopt its native conformation
and generate the intrinsic activity of an aspartic proteinase.
For the Gly-containing variant, this pre-condition is ful¢lled.
However, in the case of the Arg-containing variant, since this
absolute requirement is not met, this would suggest that trans-
lation of these (pro)napsin B clones would not generate an
active enzyme. The possibility exists that these clones may
have been derived from a transcribed pseudogene and, if
this should prove to be the case, then there would be no
requirement to maintain a stop codon under these circum-
stances. Irrespective of this Gly/Arg polymorphism, an in-
frame stop codon was not detected in the sequences deter-
mined for any of the (pro)napsin B clones.
By comparison with the ¢ve other human aspartic protein-
ases, the cDNA sequences of (pro)napsin A and B at their
respective 3P untranslated regions are both short, with only
51/48 bp respectively (75% identity) between the TGA stop
codon/TGC codon (bp 1261^1263; Fig. 1) of (pro)napsin A/B
respectively and the AGTAAA putative polyadenylation site
motif that is present in both sequences at just over 20 bp
upstream from the poly(A) tail. Thus, in the absence of an
in-frame stop codon in (pro)napsin B, the C-terminal ‘tail’
that was discussed earlier for mature napsin A would be ex-
tended even further by a minimum of 25 residues before the
introduction of multiple lysine residues as a consequence of
translation of the poly(A) tract in the (pro)napsin B message.
A mechanism has been reported in prokaryotic cells [19] for
terminating protein translation of defective mRNAs such as
those lacking a stop codon, by cotranslational switching of
the ribosome to a ubiquitous 10Sa RNA that does have an in-
frame stop codon. The consequence of these events is the
condemnation of the translated protein product to rapid deg-
radation by energy-dependent bacterial proteinases [20]. It
was hypothesised [19] that such a mechanism might also be
operative within eukaryotic cells and if this is the case, then
any (pro)napsin B protein that is translated may be subject to
rapid degradation.
The distribution of (pro)napsin A/B messages in tissues and
cells was examined by Northern blotting using a probe de-
rived from the 3P end of (pro)napsin B. The most abundant
message was found in lung (Fig. 3, top panel) with a some-
what lower level of transcription apparent in kidney, spleen
and leukocytes. The transcript size at V1.6 kb is consistent
with that predicted from the sequence(s) determined. In trans-
formed cell lines, abundant message was detected in promye-
locytic leukaemia and Raji cells, both derived from immune-
origin lineages (Fig. 3, bottom panel). However, the probe
used in these Northerns did not permit distinction between
(pro)napsin A and B mRNAs (which have an identity of
86.8% over the length of the probe). Distinction was made
possible by a knowledge of the completely conserved exon/
intron boundaries in the genomes of the ¢ve other human
aspartic proteinases (plus genomic DNAs of aspartic protein-
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ases from other mammals [9,21]). In this way, primers speci¢c
for exon 5 were designed and used in RT-PCR to amplify
message(s) prepared from lung, kidney, spleen and Raji cells.
These primers do not in themselves permit discrimination but
amplify (reverse-transcribed) message(s) for both (pro)napsin
A and B. However, the resultant amplicons di¡er in that the
BstXI site present in the (pro)napsin A sequence (at bp 550;
Fig. 1) is absent from the (pro)napsin B sequence; and con-
versely, (pro)napsin A does not contain the MspAI site (at bp
606) that is present in the (pro)napsin B sequence (see Section
2). Analysis of 19 independent clones from human lung re-
vealed that all 19 contained (pro)napsin A inserts. In parallel,
18 of 18 clones from human kidney mRNA were also of
(pro)napsin A origin. The message that is present in human
lung and kidney as revealed on the Northern blots (Fig. 3) is
thus that of (pro)napsin A. In contrast, when 23 independent
clones from spleen mRNA were analysed in the same way, all
23 were found to contain (pro)napsin B. Thus, it would ap-
pear likely that cells derived from/destined for the immune
system do not transcribe the message for (pro)napsin A, but
rather produce the (pro)napsin B message. In keeping with
this, when human Raji cells were used as one of the sources
of mRNA (see earlier), analysis by the exon 5 RT-PCR meth-
od revealed that they did not contain (pro)napsin A message.
Only (pro)napsin B mRNA was detected (20/20 clones) and
this contained the VHydrophobic-Hydrophobic-ArgV var-
iant in the psi loop as discussed earlier. It would thus appear
that, although considerable identity in sequence exists along
the length of the transcribed messages for (pro)napsins A and
B, there must be distinct di¡erences in nucleotide sequence in
the 5P £anking regions of each gene in order to achieve such
speci¢c transcription from the (pro)napsin A promoter in the
lung and kidney yet produce only (pro)napsin B mRNA in
immune cells.
During these analyses, it became apparent that yet further
EST clones, allegedly of human origin, were in reality derived
from mouse (e.g. Genbank AA074707 and AA074174). A full-
length cDNA sequence (including the (amended) sequence of
I.M.A.G.E. Consortium clones ID 531607 and 644880) was
derived in this way for mouse (pro)napsin ; its translation
product is aligned with those for human (pro)napsin A and
(pro)napsin B in Fig. 2. While this work was nearing comple-
tion, Mori et al. [22] reported the cDNA sequence of a mouse
aspartic proteinase-like protein (KAP) which is identical to
that of mouse (pro)napsin (Fig. 2). The identities between
mouse napsin and human napsin A are 78.8% (nucleotide)
and 72.6% (amino acid) respectively and between mouse and
human napsin B are 77.2% and 70.1% over the mature en-
zyme regions. Mouse napsin also contains an RGD motif and
does have an in-frame stop codon in a comparable position to
that of human napsin A (Fig. 2). We have not, to date, been
able to detect any indication of the presence of two closely
related genes in mouse so that it would appear that mouse
napsin is the equivalent murine proteinase to human napsin
A. If human napsins A and B have arisen by gene duplication,
then this event appears to have taken place relatively recently
in evolutionary terms, after the mouse and human divergence.
The present evidence thus points to the likelihood that nap-
sin A is a functional aspartic proteinase predominantly of
lung and kidney, that has not been detected hitherto. In con-
trast, the possibility exists that human (pro)napsin B may be a
transcribed pseudogene. Transcription produces a full-length
mRNA that maintains the correct reading frame up to,
through, and past the equivalent positions (Fig. 1) where
the stop codons are located in the open reading frames of
mouse and human (pro)napsin A. If this message is translated
into (pro)napsin B protein, the absence of an in-frame stop
codon suggests that the protein product may be rapidly de-
graded and thus is unlikely to accumulate to signi¢cant levels.
Detailed analyses at the protein level are now under way to
attempt to unravel these complexities associated with this new
type of aspartic proteinase.
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